EUROSETS
3.2.2021 09:32:12 CET | Business Wire | Press release
Eurosets , a leader in the development, production and commercialization of advanced medical devices, announces the full commercial release of its novel ECMOlife system for ExtraCorporeal Life Support (ECLS) . This release comes after a successful pre-market clinical evaluation in which critically ill patients were supported by the device for a cumulative period of over 400 days with the longest individual treatment lasting 27 days.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210203005034/en/
ECMOlife expands Eurosets' portfolio to provide temporary support to patients in different therapeutic areas, including ExtraCorporeal Membrane Oxygenation (ECMO) and Mechanical Circulatory Support (MCS). These therapies are used to treat patients suffering from ventricular disease, cardiac arrest or respiratory failure resulting from acute respiratory distress syndrome (ARDS), H1N1, SARS, or COVID-19 infections .
ECMOLife is a life-saving device that is able to temporarily replace the functions of severely compromised heart and lungs. The device acts as an external artificial organ connected to the patient through the main blood vessels and is used in cases where pharmacological therapy is considered insufficient.
Featuring a magnetic-levitating centrifugal pump, optimal performance and enhanced biocompatibility, ECMOlife is the most gentle, safe and versatile solution for ECLS . It is also the only device available on the market with an integrated backup system, ensuring greater patient safety and easier management for healthcare professionals even during extra-hospital transports .
ECMOlife underwent a pre-market evaluation across nine centers in Europe. The device was adopted for treatment of critically ill Covid-19 patients when mechanical ventilation was unsuccessful, as well as patients suffering from post-cardiotomy cardiogenic shock, undergoing lung transplant or requiring cardiopulmonary assistance.
One of the first centers to use ECMOlife was the University Hospital of Brussels . The ECLS team, led by Prof. Dr. Meir , Head of Cardiac Surgery, Prof. Dr. De Waele , Head of the ICU and Dr. Kurt Staessens , Head of the Cardiovascular Perfusion Group, reported about their experience: “We are really pleased with the performance of ECMOLife. The magnetic levitation technology can reduce the level of hemolysis and the risk of thrombus generation. In addition, the non-invasive monitoring system combined with the unique integrated backup unit may improve patient care, ensuring additional safety in the event of an emergency".
"Our mission is to offer new solutions to patients who do not benefit from traditional therapies and ECMOLife is fully in line with these core beliefs”, said Antonio Petralia, Executive Vice President & CEO of Eurosets . "Our device supported critically ill patients for 6 months since its pre-market clinical evaluation release in Europe and we are now very proud to have it fully available to help patients and clinicians worldwide."
View source version on businesswire.com: https://www.businesswire.com/news/home/20210203005034/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Gencom Acquires Rosewood London, Expanding Its Footprint With Its First Luxury Hotel Acquisition in Europe3.11.2026 19:05:00 CET | Press release
Located in one of the world’s most prestigious hospitality corridors, the acquisition of the 308-key hotel represents a major milestone in the firm’s international growth. Gencom, a U.S.-based investment firm that owns and develops prized real estate around the world, announces the acquisition of Rosewood London, the landmark 308-key luxury hotel situated at 252 High Holborn in Central London. The acquisition strengthens Gencom’s global hospitality investment platform and expands its presence in Europe through its first luxury hotel asset in London. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103137897/en/ Gencom, a U.S.-based investment firm that owns and develops prized real estate around the world, announces the acquisition of Rosewood London in Central London London is one of the world’s most supply-constrained hospitality markets, supported by year-round demand from both leisure and business travelers. The acquisi
SGCA Honours Communication Excellence Across Asia, Europe and the Arab World3.11.2026 16:52:00 CET | Press release
His Highness Sheikh Dr Sultan bin Ahmed bin Sultan Al Qasimi, Deputy Ruler of Sharjah and Chairman of the Sharjah Media Council, honoured winners of the 13th Sharjah Government Communication Award (SGCA), organised by the Sharjah Government Media Bureau (SGMB). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103972039/en/ SGCA honours communication excellence across Asia, Europe and the Arab world (Photo: AETOSWire) Winners represented China, India, Thailand, Ukraine and the Arab world. Some 433 entries from 31 countries across four continents passed initial screening. The award covered 23 categories across five sectors, including six partner awards. His Excellency Tariq Saeed Allay, Director General of SGMB, highlighted the award’s growth under the vision of His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, noting that it had attracted more than 9,500 entries over five year
BioLife to Showcase Oral Peptide Delivery Technology During London Life Sciences Week3.11.2026 16:03:00 CET | Press release
Company to highlight granted patent portfolio, preclinical semaglutide data and potential applications across future peptide medicines at LSX Investival BioLife Products Limited today announced its participation in London Life Sciences Week, where it will highlight its patented oral peptide delivery technology and recent advances in its intellectual property portfolio. BioLife will present at the LSX Investival Showcase on Monday, November 16, 2026, from 3:15 to 3:30 p.m. GMT, at Old Billingsgate, London. The presentation will be led by Former US Ambassador James P. Cain, Strategic Advisor to the Chairman & Founder, alongside Ludivine Delattre, Business and Corporate Relations, and will highlight the scientific journey behind the technology and its potential applications. BioLife is focused on developing a novel approach to delivering peptide therapeutics orally. Built on over 35 years of pharmaceutical effervescence expertise and two decades of oral peptide research by founder and inv
Sceye and SoftBank Corp. Sign Agreement for Fleet of Stratospheric Platforms Targeting Nationwide Coverage in Japan3.11.2026 16:00:00 CET | Press release
Five-year agreement builds on Sceye’s successful stratospheric connectivity tests in Japan and advances full-scale deployment of HAPS as stratospheric infrastructure and a key pillar of SoftBank’s strategy for a Ubiquitous Network Sceye, a U.S. aerospace and material science company building High Altitude Platform Systems (HAPS) for stratospheric infrastructure, today announced a five-year Master Services Agreement (MSA) with SoftBank Corp. (TOKYO:9434, “SoftBank”) to manufacture, launch, and operate a fleet of Sceye’s HAPS over Japan with the aim of achieving nationwide coverage. This agreement advances the companies’ partnership from flight demonstrations toward full-scale stratospheric infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103391128/en/ Sceye and SoftBank Corp. Sign Agreement for Fleet of Stratospheric Platforms Targeting Nationwide Coverage in Japan Sceye’s HAPS will form a key pillar of SoftB
Organigram to Acquire Aurora andEstablish a Global Cannabis Leader3.11.2026 15:16:00 CET | Press release
Organigram to acquire Aurora for C$7.80 per Aurora Common Share; Aurora shareholders will have the option to receive such Consideration in cash, Organigram shares or a combination of both, subject to proration. Transaction provides Aurora shareholders with certainty of value, meaningful immediate liquidity and participation in the combined entity Offer represents a 93% premium to Aurora’s Unaffected Share Price on August 10, 20261 and a 21% premium to the implied value of the unsolicited Curaleaf Hostile Bid as of November 2, 20262, unanimously rejected by Aurora’s Board of Directors Organigram shareholders to participate alongside Aurora shareholders in a company with greater scale, enhanced supply chain certainty, global footprint and diversification The combined company will own and operate five EU-GMP certified production and distribution facilities and bring world-class innovation to existing and new markets to meet international demand and support global market share expansion Th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom